Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling
Abstract
Bacillus Calmette–Guérin (BCG) therapy is one of the oldest tumor immunotherapies, but its mechanism remains unknown. Herein we show that BCG therapy induces tumor-specific T cell-dependent immunity that is predominantly mediated by CD4 T cells in a manner distinct from other tumor immunotherapies. These immunologic insights may allow investigation into biomarkers that could predict the efficacy of BCG in human cancer patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 17, 2020
- Source ID
- 10.1073/pnas.2004421117
Entities
People
- Anna Binyamin
- Anthony C Antonelli
- Gil Redelman-Sidi
- Michael S Glickman
- Tobias M Hohl
Organizations
- Burroughs Wellcome Fund
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- United States Department of Defense
- Weill Cornell Graduate School of Medical Sciences